Noumed Pharmaceuticals, the Australian subsidiary of UK-based pharmaceutical company Noumed Life Sciences, is developing a new manufacturing plant in Adelaide, South Australia (SA).
The development marks the company’s inaugural production facility in the country.
Recommended White Papers
Recommended Buyers Guides
The facility is designed to produce a range of over-the-counter (OTC) pharmaceuticals for the local market.
The project will provide Noumed’s customers with enhanced supply chain efficiency, including reduced lead times while catering to specific market demands more responsively.
Noumed is investing approximately A$100m ($65.6m) in the new facility.
The ground-breaking ceremony for the facility was held in February 2024, with the opening of the plant anticipated in 2026.
The construction phase is expected to generate 250 jobs.
The facility will offer 180 permanent positions in various fields, including pharmacy, science, engineering, and logistics, upon completion.
Location
The new plant is situated within Nexus North Industrial Estate, a master-planned industrial park at Level 3, 89 Pirie Street, Adelaide, SA.
The estate is owned and developed by Terre Property Partners, a property development and investment manager.
It is set to host a mix of national and international companies, including Asahi, Telstra, Haighs Chocolates, and FJT Logistics.
Noumed’s pharmaceutical manufacturing facility details
Noumed’s pharmaceutical manufacturing facility will span an area of 43,000m² with a building floor space of 26,000m².
The facility’s initial operational phase will focus on the production of liquid formulations such as cough syrups, paediatric suspensions, creams and nasal sprays, in addition to the packaging of solid dose tablets.
A subsequent phase will expand the facility’s capabilities to include the manufacturing of solid dose tablets.
Upon reaching full operational capacity, the plant will have an annual production capacity of 40 million units, comprising tablets, liquid formulations, and creams.
The output is intended to supplant the volume of products currently manufactured by Noumed in the UK.
Funding
Noumed Pharmaceuticals was granted funding of A$20m by the Australian Government through the Modern Manufacturing Initiative.
The initiative is part of a broader ten-year strategy aimed at advancing the health and medical industries in the region.
Contractors involved
Bell Architecture, an architecture company, is responsible for providing architectural, interior, and landscape design services.
TMX Transform, a supply chain consultant, and FDC Construction & Fitout, a construction, fitout, refurbishment and building services provider, is responsible for the project’s design and development.
Real estate services for the project are facilitated by commercial real estate and investment management company JLL, in partnership with Terre Property Partners, acting as the leasing agent for Noumed.
Various consultants and engineering companies, including MinterEllison, Lucid Consulting Australia, Triaxial Consulting, WGA Consulting Engineers, Fe Portal, and Cirqa Traffic are also involved in the project.
Marketing commentary on Noumed Pharmaceuticals
Noumed Pharmaceuticals is an OTC pharmaceutical company.
The company operates a 3,000m² warehouse in Adelaide, serving as a hub for the distribution of its products nationwide.
The parent company, Noumed Life Sciences, specialises in the production of solid dosage forms such as tablets and capsules.
It also maintains research and development suites for new product development, including conducting trials and manufacturing small batches for clinical testing.
The company’s product range spans antacids, antiarrhythmics, antibiotics, anticonvulsants, antidepressants, antidiarrheals, antifungal medicines, antihistamines, antihyperglycemics, anti-inflammatory drugs, antispasmodics, opioid drugs, vitamins and beta blockers.
The manufacturing capabilities are complemented by advanced packaging lines, which include features such as automatic cartoning, track-and-trace systems, banding, and 2D barcoding, ensuring efficiency and compliance with regulatory standards.
